Preclinical antitumour activity of F 11782, a novel dual catalytic inhibitor of topoisomerases

British Journal of Cancer

Volumn 83, Issue 11, 2000, Pages 1516-1524

  Kruczynski, A ^a,d   Etievant C ^a   Perrin, D ^a   Imbert, T ^b   Colpaert, F ^c   Hill, B T ^a  

^a Division of Experimental Cancer Research   (France)

^b Division of Medicinal Chemistry   (France)

^c Research Centre Directorate   (France)

^d INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Dual topoisomerase inhibitor; In vivo cancer chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; F 11782; GYRASE INHIBITOR; PODOPHYLLOTOXIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; FEMALE; IN VIVO STUDY; LEUKEMIA; LUNG CANCER; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR XENOGRAFT;

EID: 0033676376     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1428     Document Type: Article

References (23)

1. Experimental antitumour activity of taxotere (RP 56976, NSC 628503), a taxol analogue
2. Combined in vitro/in vivo test procedure with human tumour xenografts for new drug development
3. Antitumour activity of a novel quinolone derivative, TAS-103, with inhibitory effects on topoisomerases I and lI
4. Topoisomerase poisons: Harnessing the dark side of enzyme mechanism
5. Drugs acting on DNA topoisomerases: Recent advances and future perspectives
6. Comparative antitumour activity of vinblastineisoleucinate and related vinca alkaloids in human tumour xenografts
7. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumour: Demonstration of tumour-type specificity and implications for cancer chemotherapy
8. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisia
9. Merbarone, a catalytic inhibitor of DNA topoisomerase II, induces apoptosis in CEM cells through activation of ICE/CED-3-like protease
10. Preclinical in vivo antitumour activity of vinflunine, a novel fluorinated Vinca alkaloid
11. Preclinical phase II studies in human tumour xenografts: A European multicenter follow-up study
12. Human tumour xenografts in athymic nude mice as a preclinical screen for anticancer agents
13. F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action
14. Human tumour xenograft models in NCI drug development
15. DNA topoisomerase II inhibitors
16. Efficacy of lonidamine combined with different DNA-damaging agents in the treatment of the MX-1 tumour xenografts
17. Inhibition of eukaryotic DNA topoisomerase I and II activities by indoloquinolinedione derivatives
18. Preclinical antitumour activity of a soluble etoposide analog, BMY-10481-30
19. Antitumour activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer
20. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumours of the ovary, before and after platinum/cyclophosphamide chemotherapy
21. Relevance of transplantable animal-tumour systems to the selection of new agents for clinical trials
22. Preclinical drug development: Rationale and methods
23. Induction of mammalian DNA topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumour agent from fungus